- Home
- BMEA vs USAU Comparison
BMEA vs USAU Comparison
Compare BMEA & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- USAU
- Stock Information
- Founded
- BMEA 2017
- USAU 2014
- Country
- BMEA United States
- USAU United States
- Employees
- BMEA 63
- USAU N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- USAU Precious Metals
- Sector
- BMEA Health Care
- USAU Basic Materials
- Exchange
- BMEA Nasdaq
- USAU Nasdaq
- Market Cap
- BMEA 96.9M
- USAU 126.8M
- IPO Year
- BMEA 2021
- USAU N/A
- Fundamental
- Price
- BMEA $1.36
- USAU $15.28
- Analyst Decision
- BMEA Strong Buy
- USAU Strong Buy
- Analyst Count
- BMEA 7
- USAU 3
- Target Price
- BMEA $8.86
- USAU $19.00
- AVG Volume (30 Days)
- BMEA 1.7M
- USAU 342.2K
- Earning Date
- BMEA 11-04-2025
- USAU 12-15-2025
- Dividend Yield
- BMEA N/A
- USAU N/A
- EPS Growth
- BMEA N/A
- USAU N/A
- EPS
- BMEA N/A
- USAU N/A
- Revenue
- BMEA N/A
- USAU N/A
- Revenue This Year
- BMEA N/A
- USAU N/A
- Revenue Next Year
- BMEA N/A
- USAU N/A
- P/E Ratio
- BMEA N/A
- USAU N/A
- Revenue Growth
- BMEA N/A
- USAU N/A
- 52 Week Low
- BMEA $1.22
- USAU $5.59
- 52 Week High
- BMEA $8.99
- USAU $19.20
- Technical
- Relative Strength Index (RSI)
- BMEA 40.15
- USAU 44.27
- Support Level
- BMEA $1.22
- USAU $14.43
- Resistance Level
- BMEA $1.35
- USAU $16.00
- Average True Range (ATR)
- BMEA 0.10
- USAU 0.75
- MACD
- BMEA 0.00
- USAU -0.30
- Stochastic Oscillator
- BMEA 31.16
- USAU 22.22
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.